SAB Biotherapeutics Inc Ordinary Shares SABS 深 滬
已收盤 12-24 16:00:00 美东时间
3.84
0.000
0.00%
華盛通- 最 高3.945
- 今 開3.86
- 成交量 5.58万股
- 最 低 3.80
- 昨 收 3.84
- 總市值 3997.86万
- 52周最高 6.60
- 市盈率 靜 --
- 換手率 0.54%
- 52周最低 1.00
- 委 比 91.37%
- 總股本 1041.11万
- 歷史最高 129.00
- 量 比 0.12
- 振 幅 3.78%
- 歷史最低 1.00
- 每 手 1
- 風險率 0.84%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后评级出炉！联邦快递获多家大行上调目标价；耐克遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Pyxis Oncology"买入"评级，目标价从5美元升至7美元；Stifel：维持Oculis Holding"买入"评级，目标价从35美元升至40美元
12-22 15:05
SAB Biotherapeutics Announces Confirmatory Data From Phase 1 Trial Of SAB-142 In Single- And Multiple-Ascending Dose Among Healthy Volunteers, Including Re-Dosed Cohort, And T1D Patients
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing of SAB-142 in
12-17 21:05
SAB Biotherapeutics To Highlight Data Showcasing Progress In Development Of SAB-142 At ATTD-Asia
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced
12-08 21:11
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Chardan Capital Maintains Buy on SAB Biotherapeutics, Maintains $12 Price Target
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $12 price target.
11-17 20:13
SAB Biotherapeutics To Present Phase 1 Data Demonstrating SAB-142's Multi-Specific Mechanism Of Action, Sustained Immunomodulation, Favorable Safety Profile Without Serum Sickness Or Anti-Drug Antibodies, And A Novel Pharmacokinetic Assay For Measuring The Drug
SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that
11-04 21:37
SAB Biotherapeutics Board Members Resign in Agreement
SAB Biotherapeutics ( ($SABS) ) has provided an announcement. On September 30, ...
10-01 04:59
SAB Biotherapeutics Approves Equity Plan Amendments
SAB Biotherapeutics ( ($SABS) ) has issued an announcement. On September 26, 20...
09-27 05:16
美股大行评级 | 潜在涨幅302.68%！Maxim Group上调T Stamp目标价至12美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持T Stamp"买入"评级，目标价从8美元升至12美元；Maxim Group：维持Rezolute"买入"评级，目标价从15美元升至20美元
09-22 18:44
SAB BIO Highlights Data in Multiple Presentations at EASD
SAB Biotherapeutics highlighted its Phase 2b SAFEGUARD study of SAB-142 for new-onset Stage 3 autoimmune type 1 diabetes (T1D) at the EASD Annual Meeting. Presentations emphasized SAB-142's multi-specific, potentially best-in-class immunomodulatory approach, which avoids sustained lymphodepletion unlike rabbit ATG. Data from Phase 1 studies demonstrated its safety and efficacy, with initial findings from INNODIA’s MELD-ATG trial supporting SAB-14...
09-19 11:24
